肿瘤药断供数月，患者“自费1万多元1瓶还买不到”

Core Viewpoint - Shanghai Yingli Pharmaceutical Co., Ltd. is facing operational challenges, including relocation due to disputes with the landlord, despite claiming that all business activities are proceeding normally [1][5][6]. Group 1: Company Operations - The company has confirmed that it is undergoing a relocation process primarily due to rental disputes, not operational issues [2][3]. - As of the latest reports, the company has around 30 employees remaining, and it is in the process of packing and moving equipment [3][4]. - Yingli Pharmaceutical has stated that all research, production, and operational activities are progressing as planned, with no abnormal circumstances affecting normal operations [5][6]. Group 2: Product Supply Issues - The core product, Linpulise (also known as "因他瑞"), has been experiencing supply shortages since the fourth quarter of 2025, affecting patients who rely on this medication [7][8]. - Patients have reported that the promised drug donation programs have not been fulfilled, leading to further distress among those dependent on Linpulise [8]. - The drug's price is set at 11,040 yuan per bottle, and its removal from the national medical insurance directory has significantly impacted its market accessibility [10]. Group 3: Legal and Financial Challenges - Yingli Pharmaceutical has been involved in over 30 lawsuits since 2025, primarily related to contract disputes with suppliers and service providers [11]. - The company has been ordered to pay approximately 2.25 million yuan due to a service contract dispute, which has also led to restrictions on its legal representative [11]. - The financial strain from these legal issues and operational challenges has raised concerns about the company's future viability and its reliance on a single product [10][11].